Physician profile
James Lisi
NPI 1023101391
$1,596.01
in general payments reported to CMS, 2019-2025
13 companies · $810 in 2025
The $810 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $254 · 2024: $325 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.82 | 2022-2025 | |
| Janssen Biotech, INC. | $183.91 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $121.08 | 2023 | Zeposia |
| Lilly USA, LLC | $98.70 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $88.61 | 2024-2025 | Vowst |
| Pfizer INC. | $79.81 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.96 | 2024-2025 | Entyvio |
| Genzyme Corporation | $20.29 | 2025 | |
| Celgene Corporation | $18.35 | 2024 | Zeposia |
| Qol Medical, LLC | $17.25 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $16.69 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $15.58 | 2023 | |
| Merck Sharp & Dohme LLC | $14.96 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.